![](https://webarchive.library.unt.edu/eot2008/20090115030254im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115030254im_/http://www.cancer.gov/images/spacer.gif)
chimeric anti-phosphotidylserine monoclonal antibody An IgG3 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Chimeric anti-phosphotidylserine monoclonal antibody binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115030254im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090115030254im_/http://www.cancer.gov/images/spacer.gif) | Tarvacin | | ![](https://webarchive.library.unt.edu/eot2008/20090115030254im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090115030254im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115030254im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115030254im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115030254im_/http://www.cancer.gov/images/spacer.gif) |